(Q34545573)

2 August 2017

title

Oral acyclovir for herpes zoster ophthalmicus (English)

1 reference

2 August 2017

1 reference

1 reference

Hoang-Xuan T

1

1 reference

2 August 2017

Büchi ER

2

1 reference

2 August 2017

Herbort CP

3

1 reference

2 August 2017

Denis J

4

1 reference

2 August 2017

Frot P

5

1 reference

2 August 2017

Thénault S

6

1 reference

2 August 2017

Pouliquen Y

7

1 reference

2 August 2017

publication date

1 July 1992

1 reference

2 August 2017

1 reference

2 August 2017

volume

99

1 reference

2 August 2017

issue

7

1 reference

2 August 2017

page(s)

1062-70; discussion 1070-1

1 reference

The natural history of herpes zoster

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Complications of herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

The varicella-zoster virus: Systemic and ocular features

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Observations on the natural history of herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Herpes zoster dendritic keratitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

In vitro susceptibility of varicella-zoster virus to acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Pathogenesis of varicella-zoster angiitis in the CNS

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Herpes zoster ophthalmicus with contralateral hemiplegia: identification of cause

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acyclovir in herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acyclovir therapy for acute herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Intravenous acyclovir in acute herpes zoster infection

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

High-dose intravenous acyclovir in the treatment of zoster: A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acyclovir administered perorally in immunocompromised children with varicella-zoster infections

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir for herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir for herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir in the therapy of acute herpes zoster ophthalmicus. An interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir in the treatment of acute herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Pharmacokinetics of acyclovir after intravenous and oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Pharmacokinetics of oral acyclovir (Zovirax) in the eye.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir in herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Oral acyclovir in the treatment of acute herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

[Prevention of ocular complications of herpes zoster ophthalmicus by adequate treatment with acyclovir]

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Treatment of shingles and post-herpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acyclovir and post-herpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Cutaneous eruption with or without ocular complications in patients with herpes zoster involving the trigeminal nerve

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

High-dose oral acyclovir in acute herpes zoster ophthalmicus: The end of the corticosteriod era

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Topical acyclovir in herpes zoster ocular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Acute herpetic and postherpetic neuralgia: clinical review and current management

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Do corticosteroids prevent post-herpetic neuralgia?

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Prednisolone does not prevent post-herpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Treatment of Acute Herpes Zoster with Amantadine Hydrochloride (Symmetrel)

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

Lack of effect of acyclovir on postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2892%2931849-4

7 January 2021

10.1016/S0161-6420(92)31849-4

Identifiers

DOI

1 reference

2 August 2017

1 reference